+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
MALE
ID05593497

Evaluating Neoadjuvant Capivasertib with Intensified Androgen Deprivation before Radical Prostatectomy for High-Risk Localized Prostate Cancer Showing PTEN Loss

Led by VA Office of Research and Development · Updated on 2026-10-26

30

Participants Needed

9

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating a new treatment approach for men with high-risk localized prostate cancer that does not respond well to standard therapies. This phase II study focuses on cancers with PTEN loss, a genetic change linked to more aggressive tumors and resistance to usual androgen therapies. The study aims to evaluate a combination of intensified androgen deprivation drugs and an AKT inhibitor before prostate surgery to see if it can reduce tumor size and improve outcomes. Participants will take the study drug capivasertib along with abiraterone and leuprolide as intensified androgen deprivation therapy. The treatment starts with a 4-week run-in period of abiraterone and leuprolide, followed by a 16-week combined therapy with capivasertib given intermittently on a weekly schedule. After completing drug treatment, participants will undergo radical prostatectomy with lymph node dissection as the standard surgical care. During the study, participants will be closely monitored with tissue biopsies and pathological assessments to measure tumor response, including checking for complete response or minimal residual disease at surgery. Safety and surgical complications will also be tracked. The total study duration includes drug treatment and follow-up assessments over approximately five months, with additional 90-day monitoring for complications after surgery. Researchers will use these results to understand the treatments effects on tumor biology and surgical outcomes.

CONDITIONS

Brief Title

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

Research Team

R

Ryan P Kopp, MD

L

Laura Onstad, RN

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here